Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment

Psychiatric Services

Volumn 67, Issue 6, 2016, Pages 676-679

  Saloner, Brendan ^a   Stoller, Kenneth B ^b   Barry, Colleen L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; DRUG UTILIZATION; FEMALE; FUNDING; HEALTH CARE POLICY; HUMAN; MALE; MEDICAID; METHADONE TREATMENT; OPIATE ADDICTION; OUTPATIENT CARE; SUBSTANCE USE; ECONOMICS; OPIATE SUBSTITUTION TREATMENT; QUESTIONNAIRE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANALGESICS, OPIOID; FEMALE; HUMANS; LINEAR MODELS; MALE; MEDICAID; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84989963213     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201500228     Document Type: Article

References (15)

1. Mattick RP, Breen C, Kimber J, et al: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2:CD002209, 2003
2. Connock M, Juarez-Garcia A, Jowett S, et al: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment 11:1-171, iii-iv, 2007
3. Fingerhood MI, King VL, Brooner RK, et al: A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. Substance Abuse: Research and Treatment 35:122-126, 2014
4. Gelber Rinaldo S, Rinaldo DW: Availability without accessibility? State Medicaid coverage and authorization requirements for opioid dependence medications; in Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment. Chevy Chase, Md, American Society of Addiction Medicine, 2013
5. Knopf A: Maine governor proposes to eliminate Medicaid funding for OTPs. Alcoholism and Drug Abuse Weekly 27:1-4, 2015
6. Jones CM, Campopiano M, Baldwin G, et al: National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health 105:e55-e63, 2015
7. Ducharme LJ, Abraham AJ: State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 3:17, 2008
8. McCarty D, Frank RG, Denmead GC: Methadone maintenance and state Medicaid managed care programs. Milbank Quarterly 77: 341-362, 1999
9. Deck DD, Wiitala WL, Laws KE: Medicaid coverage and access to publicly funded opiate treatment. Journal of Behavioral Health Services and Research 33:324-334, 2006
10. Buck JA: The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs 30:1402-1410, 2011
11. Gfroerer J, Bose J, Trunzo D, et al: Estimating Substance Abuse Treatment: A Comparison of Data From a Household Survey, a Facility Survey, and an Administrative Data Set. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2014
12. 2011 Opioid Treatment Program Survey: Data on Substance Abuse Treatment Facilities with OTPs. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2013
13. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2014
14. Rosenblatt RA, Andrilla CHA, Catlin M, et al: Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Annals of Family Medicine 13:23-26, 2015
15. Busch SH, Meara E, Huskamp HA, et al: Characteristics of adults with substance use disorders expected to be eligible for Medicaid under the ACA. Psychiatric Services 64:520-526, 2013